Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Dr. Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Commonwealth Scientific and Industrial Research Organisation | Australia

Dr. Michela Simone is a distinguished scientist with expertise spanning green chemistry, renewable energy, carbohydrate chemistry, glycobiology, ionic liquids, spectroscopy, medicinal chemistry, and synthetic developments. With a multicultural background and fluency in multiple languages, she has built a global research profile, contributing significantly to sustainability and pharmaceutical sciences. Currently serving as a Research Scientist at CSIRO in Australia, she leads and supports projects focused on sustainable carbon technologies and carbon capture efficiency. Her earlier career included leadership as a CERC Fellow at CSIRO, lecturer roles at the University of Newcastle and University of Sydney, and postdoctoral research at the University of Oxford and University College London. She has published extensively in high-impact journals, authored book chapters, and holds patents in hydrogen production and drug development. Her academic and industrial collaborations highlight her interdisciplinary approach, bridging fundamental research with applied solutions to address pressing global challenges in energy, health, and sustainability.

Profile

Google scholar

ORCID

Education

Dr. Michela Simone earned her Doctor of Philosophy from the University of Oxford, where she conducted pioneering research on branched sugar lactones under the mentorship of Professor George W. J. Fleet at the Dyson Perrins Laboratory and Chemistry Research Laboratory. Prior to this, she completed her Master of Science with first-class honours at the Victoria University of Manchester, focusing on the synthesis of muscarinic receptor agonists under Professor E. James Thomas. During her studies, she was awarded a European Union Socrates Award for an exchange program at the Georg-August University of Göttingen in Germany, where she worked on chemical and biological syntheses of pyripyropenes under Professor Uwe Beifuss. This international academic training provided her with a strong foundation in synthetic organic chemistry, carbohydrate chemistry, and medicinal chemistry. Her educational journey laid the groundwork for her later achievements in spectroscopy, drug discovery, and renewable energy research, demonstrating her ability to bridge chemistry with interdisciplinary applications.

Experience

Dr. Michela Simone’s professional journey reflects a balance of academic scholarship, research innovation, and industrial collaboration. Currently, she works at CSIRO as a Research Scientist in the Sustainable Carbon Technologies Group, where she applies her mechanistic and spectroscopic expertise to optimize carbon capture processes for industrial applications. Previously, as a CERC Fellow at CSIRO, she led a major project on sustainable hydrogen production, integrating physical chemistry, engineering, and physics, resulting in a patent for water-splitting processes. Her academic career includes tenure as a Lecturer in Medicinal Chemistry and Chemical Biology at the University of Newcastle, where she managed a 40:40:20 workload across research, teaching, and service while supervising her research group in glycobiology and synthetic chemistry. Earlier, she was a Lecturer in Chemistry at the University of Sydney, focusing on medicinal and biological chemistry. Her postdoctoral work at Oxford and University College London contributed to advances in protein interactions and medicinal chemistry.

Awards and Honors

Dr. Michela Simone’s career has been marked by recognition for her contributions to chemistry and interdisciplinary research. She has authored more than sixty-five peer-reviewed publications, invited book chapters, and holds patents in hydrogen production technologies and drug delivery systems, reflecting her innovative impact on both energy and healthcare. Her invited contributions to special issues in journals such as Molecules, Pharmaceuticals, and the European Journal of Medicinal Chemistry highlight her status as a recognized expert in boron chemistry, glycobiology, and green synthetic methods. She has been invited to contribute book chapters with leading publishers including Taylor & Francis, underscoring her international reputation. Her work has been spotlighted in editorial features such as “Women in Bioorganic Chemistry,” reflecting her role as a leader and role model in science. With a growing citation record, high h-index, and strong collaborations across academia and industry, she continues to be acknowledged for her research excellence and scientific leadership.

Research Focus

Dr. Michela Simone’s research focus lies at the intersection of green chemistry, renewable energy, and medicinal chemistry, with an emphasis on practical applications that address urgent global challenges. She has pioneered work in renewable fuels, including hydrogen generation, biomass conversion, carbon capture and storage, and redox flow batteries, aiming to reduce environmental impact while improving energy efficiency. Her work in carbohydrate chemistry and glycobiology has contributed to the development of high and low Fsp3 drug leads, with innovative approaches incorporating organic boron as a novel pharmacophore for medicinal chemistry and cancer therapies. She has also advanced the field of ionic liquids, exploring their potential in sustainable synthesis and material applications. Utilizing spectroscopy and mechanistic insights, she combines fundamental chemical principles with applied solutions, leading to patents and industrial collaborations. Her interdisciplinary approach integrates chemistry, physics, and engineering, establishing her as a global leader in research that bridges sustainability, energy innovation, and health.

 

Publications

 

Title: Endothelial C-type natriuretic peptide maintains vascular homeostasis
Year: 2014
Citation: 187

Title: The expanding utility of continuous flow hydrogenation
Year: 2015
Citation: 144

Title: Synchrotron based NEXAFS study on nitrogen doped hydrothermal carbon: Insights into surface functionalities and formation mechanisms
Year: 2017
Citation: 126

Title: A compendium of sugar amino acids (SAA): scaffolds, peptide-and glyco-mimetics
Year: 2007
Citation: 121

Title: Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis
Year: 2016
Citation: 111

Title: A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues
Year: 2013
Citation: 103

Title: Kiliani on ketoses: branched carbohydrate building blocks from D-fructose and L-sorbose
Year: 2004
Citation: 87

Title: Kiliani reactions on ketoses: branched carbohydrate building blocks from D-tagatose and D-psicose
Year: 2005
Citation: 79

Title: o-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity
Year: 2019
Citation: 52

Conclusion

Dr. Michela Simone is an accomplished scientist whose interdisciplinary expertise in green chemistry, renewable energy, carbohydrate chemistry, and medicinal chemistry has led to impactful research, patents, and collaborations that advance sustainability and healthcare innovation worldwide.

Manijeh Beigi | Medical Physics | Best Researcher Award

Dr. Manijeh Beigi | Medical Physics | Best Researcher Award

Dr. Manijeh Beigi is an Assistant Professor in the Radiation Oncology Department at Iran University of Medical Sciences. She specializes in dosimetry, radiotherapy treatment planning, and quality audits, with a focus on using machine learning for radiomics and dosiomics analysis. Dr. Beigi earned her Ph.D. in Medical Physics from Tehran University of Medical Sciences in 2018, where she researched the application of Diffusion Tensor Imaging (DTI) in radiotherapy planning. With over a decade of experience in radiotherapy physics, she has worked in multiple hospitals, including Imam Hosein, Haft-e-Tir, and Pardis Niloo Cancer Center. She is actively involved in research on predicting radiotherapy toxicity and advanced MR imaging applications. Dr. Beigi has mentored numerous students, contributed to high-impact journals, and presented at international conferences. Her research aims to enhance radiotherapy precision and patient safety through cutting-edge imaging and AI-driven models. 🎓🔬

Profile

Education 🎓

Dr. Manijeh Beigi holds a Ph.D. in Medical Physics (2018) from Tehran University of Medical Sciences, where she developed automated clinical target volume determination for glioma treatment using multiparametric MRI. She completed her M.Sc. in Medical Physics (2010) at Tarbiat Modares University, focusing on radiotherapy dosimetry and quality audits in Varian linear accelerators. Her coursework covered key topics such as radiotherapy physics, radiobiology, MRI, CT, and PET physics, statistical methods, and treatment planning. Throughout her academic journey, she has specialized in advanced imaging techniques, radiomics, and AI-based predictive modeling for radiotherapy applications. Dr. Beigi’s education has provided her with strong expertise in medical physics, treatment planning optimization, and quality assurance, positioning her as a leader in radiation oncology research and innovation. 📚

Experience 👨‍🏫

Dr. Manijeh Beigi has been an Assistant Professor at Iran University of Medical Sciences since 2020, where she focuses on radiotherapy physics, treatment planning, and quality assurance. Previously, she worked as a Radiotherapy Physicist at Imam Hosein Hospital (2010-2016), Haft-e-Tir Hospital (2016-Present), and Pardis Niloo Cancer Center (2019-2021), specializing in 3D conformal radiotherapy, IMRT planning, machine QA, and dosimetry. She was also a Research Assistant (2012-2018) at Tehran University of Medical Sciences, collaborating on quantitative MRI and spectroscopy research. Dr. Beigi has significant experience in mentoring students, managing research projects, and implementing AI-driven radiotherapy solutions. Her work integrates imaging and machine learning to optimize treatment efficacy and minimize patient toxicity. 💼🔬

Research Interests 🔬

Dr. Manijeh Beigi’s research centers on dosimetry, radiotherapy quality audits, and the application of machine learning in radiomics and dosiomics. She explores AI-driven models to predict radiotherapy toxicity and optimize treatment planning. Her work integrates advanced MRI techniques, such as Diffusion Tensor Imaging (DTI), to enhance clinical target volume delineation for gliomas and other cancers. She investigates imaging biomarkers to assess radiation-induced damage and improve treatment precision. Additionally, Dr. Beigi is actively involved in multi-disciplinary research collaborations, utilizing deep learning for medical image analysis. Her contributions aim to advance radiation oncology by improving accuracy, reducing side effects, and personalizing treatment plans. 🧬📡

Dr. Manijeh Beigi has received several accolades for her contributions to medical physics and radiotherapy research. She has been recognized for her work in AI-driven radiomics and dosiomics at international conferences, including ESTRO and AAPM. Her research on glioma segmentation using DTI and radiotherapy toxicity prediction has been published in top-tier journals. She has also been awarded grants for her studies on advanced MRI applications in radiotherapy planning. Additionally, Dr. Beigi has played a key role in multi-institutional research collaborations, earning recognition for her leadership in medical imaging and quality assurance. 🏆🎖️

Publications 📚

Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. 📚💡

Profile

Education 🎓

Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. 🔬📖

Experience 👨‍🏫

Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. 🌍🔬

Research Interests 🔬

Dr. Fadavi’s research centers on radiomics, predictive modeling, and improving radiotherapy outcomes. His recent studies explore machine learning applications in radiation toxicity prediction, chemotherapy delays, and novel treatment strategies for breast, cervical, and head-and-neck cancers. He investigates biomarkers for cancer prognosis and response to therapy, with a strong emphasis on precision oncology. His work in computational oncology and artificial intelligence-driven diagnostics is shaping the future of personalized cancer treatment. 💻🧬Awards & Recognitions 🏅

Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. 📜🏅

Publications 📚

Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

Prof Dr.  Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

: Sun Yat-sen University Fifth Affiliated Hospital, china

Profile

Education

Dr. Hongjun Jin is a Principal Investigator in Nuclear Medicine and a Doctoral Supervisor of Molecular Medicine at Sun Yat-sen University. He earned his PhD in Biochemistry from Texas A&M University in 2007, following a BS in Radiochemistry from Lanzhou University in 1994 and a BMed in Chinese Medicine from Beijing University of Chinese Medicine in 1997. He completed his postdoctoral training at PNNL from 2008 to 2012 and served as a radiology instructor at Washington University in St. Louis from 2012 to 2017. Since 2017, he has led the PET and radiochemical laboratory at his institute, having been recruited through Sun Yat-sen University’s “Hundred Talents Program.”

Research and Innovations:

1) General Research Fund for National Sciences Foundation of China (NSFC), 82372004,
“F-18 labelled PET probe targeting P2X7 receptor for Evaluation of Treatment for AD”
01/01/2024-12/31/2027¥480,000,
2) Key R&D project, 0007/2022/AKP, Macao S&T Fund (FDCT),“R&D of an Integrated
Molecular probe for Targeted TNFR2 New Tumor Diagnosis and
Treatment”,01/01/2024-12/31/2027,¥2,400,000 (out of ¥120,000,000)
3) Guangdong Provincial Enterprise Joint Fund, 2021A1515220004, Guangdong Province
“PET/MRI Neuromolecular Imaging Quantitative Study of New Drug Targeting Sigma1

Research Project

  • 1) Outstanding Foreign Young Scientist Talent Program, RFIS, 82150610508 NSF-CN,
    “ Establishment and drug evaluation of acetylcholinergic and dopaminergic
    neuromolecular probes (18F VAT and 18F-DTBZ) PET brain imaging quantitative
    system for Parkinson’s disease” 2022/01-2022/12,¥400,000
  • General Research Fund for NSFC, 81871382, “F-18 labelled PET probe targeting P2X7
    receptor for early detection of AD”01/01/2019-12/31/2022¥570,000
  • SYSU “Hundred Talent “Starting Fund (Period I)” SYSU-FA10/01/2017-09/30/2022
    ¥2,500,000
  • National Key R&D Program for Precision Medicine, 2018YFC0910601 Real-time, highdimensional, multi-modality imaging co-registration and theronoastic strategies for
    oesophageal squamous-cell carcinomas10/01/2018-12/31/2020¥1,272,500 (out of
    ¥19,230,000)
  • Sun Yat-sen University Military Industry Cultivation Project, 89000-18843403 SYSU
    “Key Technologies of Molecular Imaging of Immune Dysfunction in Microgravity
    Environment”, 2019/08-2021/12¥1,890,00
  • Researchers Initiate Clinical Research Project (IIT) Award, SYSU-FAH”A single-center,
    open, prospective assessment of the diagnostic significance of 18F-FDG PET/CT
    dynamic imaging and gene sequencing in detecting metastatic lesions of non-small cell
    lung cancer”,2020/10-2021/09¥50,000
  • COVID-19 infection prevention and control emergency S&T, ZH22036302200036PWC,
    Zhuhai City”Specific Targeting S- protein of SARS-CoV-2 PET molecular imaging
    probe”2020/08-2021/09,¥70,000

Citation Index:

Google Scholar Citations: 8684 (total) 7943 (since 2020)
h-index 26(total) 20 (since 2020)
i10-index 52(total) 39(since 2020)

Publications